Inogen, Inc. (INGN) 股票分析

公司概述

Inogen, Inc. operates as a medical technology company that develops, manufactures, and markets respiratory health products for patients suffering from chronic respiratory conditions who require supplemental long-term oxygen therapy, primarily utilizing portable oxygen concentrators. The company functions within the Healthcare sector and specifically targets the Medical Devices industry, positioning itself to address the growing global demand for home-based respiratory care solutions. As of the latest reporting period, Inogen, Inc. maintains a market capitalization of $181.37M, generates annual revenue of $348.67M, and employs a workforce of 753 individuals across its operational footprint. These financial dimensions indicate that the company holds a mid-cap profile with significant revenue generation capabilities relative to its asset base, suggesting a business model capable of scaling production while managing substantial human capital resources.

财务健康

Inogen, Inc. reported a trailing twelve-month revenue of $348.67M alongside a net income of $-22,747,000 and an EBITDA of $-9,548,000, revealing a cost structure where operating expenses significantly outpace gross profit generation. The company generated free cash flow of $-21,157,376, which indicates a period of negative cash generation that may reflect heavy capital expenditure on manufacturing facilities or aggressive expansion efforts rather than operational inefficiency. The company's profitability is characterized by a gross margin of 44.2%, an operating margin of -12.2%, and a profit margin of -6.5%, suggesting that while the core product sales are priced to cover variable costs, high fixed costs or sales expenses are currently eroding overall profitability. On the balance sheet, Inogen, Inc. holds cash of $119.58M against total debt of $17.48M, resulting in a debt-to-equity ratio of 9.09, which presents a complex picture of a firm with ample liquidity but a high leverage multiple relative to equity. The current ratio stands at 3.12, indicating a robust short-term liquidity position where current assets are more than three times current liabilities, providing ample buffer for immediate obligations. Furthermore, the return on equity is -12.4% and the return on assets is -6.3%, metrics that reveal management is currently allocating capital in a manner that does not yet yield positive returns on the invested equity or total asset base.

估值评估

The valuation metrics show a trailing P/E ratio of N/A and a forward P/E of -21.48, implying that the market is pricing in expected future earnings recovery rather than assessing value based on current profitability. The price-to-book ratio is 0.94, indicating that the stock trades at a slight discount to its book value, which may suggest the market is undervaluing the company's tangible assets or anticipating a prolonged period of earnings normalization. Alternative valuation measures include a price-to-sales ratio of 0.52 and an EV/EBITDA of -8.30, suggesting that investors are valuing the company primarily on its sales revenue rather than earnings power, a common approach for firms in growth or turnaround phases. The stock has a 52-week high of $9.13 and a 52-week low of $5.34, meaning the current trading price sits within this historical volatility range, though the specific current price relative to the high cannot be calculated without the live quote, the range defines the recent price discovery boundaries. The beta value is 1.71, which indicates that the stock price volatility is significantly higher than the broader market, moving approximately 71% more aggressively than the market index during periods of fluctuation.

Growth & Income

Inogen, Inc. recorded a revenue growth of 2.0% year-over-year, while earnings growth is N/A due to the negative net income, implying that top-line growth is currently decoupled from bottom-line profitability as the company works to reduce losses. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, indicating that the firm retains all of its earnings to fund operations, capital projects, or debt reduction rather than distributing cash to shareholders. The absence of a dividend payout ratio suggests a reinvestment strategy focused on sustaining growth initiatives and improving the operating margin rather than providing immediate income to investors. Overall, the growth and income profile is defined by modest revenue expansion coupled with significant investment in turning the company profitable, resulting in zero dividend income but potential for future earnings generation.